MedicinePharmacologyPharmacotherapyClinical PharmacologyNeuropharmacologySleep MedicineExcessive Daytime SleepinessHypersomnia DisordersPsychostimulant PharmacologySleep Disorder PharmacotherapySleep-wake DisordersStimulant TherapyAdrenergic SignalingCataplexy PharmacotherapyModafinil PharmacologyModafinil TherapyNarcolepsy PharmacotherapyPsychostimulant PharmacotherapyTherapeutic Use In NarcolepsyTreatment Of Hypersomnia
The efficacy of modafinil, a psychostimulant drug acting on postsynaptic alpha-1 adrenergic receptors, as a treatment for excessive daytime sleepiness was studied in 123 patients. Subjects included 94 narcoleptic patients (76 with cataplexy), 23 hypersomnia patients and 6 patients with disrupted nocturnal sleep (DNS) and excessive daytime sleepiness (EDS). Clinical efficacy of the treatment on each symptom (EDS, cataplexy and DNS) was evaluated on a four-point scale from excellent to absent. The effectiveness of modafinil as a treatment for EDS was excellent in 17% of all patients, good in 63%, fair in 17% and absent in 3%. The incidence of side effects was rather low (14 of 123 patients) and most of them disappeared (11 patients) when doses were reduced.